Philadelphia, PA, December 2, 2014 - Persistent anxiety is one of the most common and distressing symptoms compromising mental health. Most of the research on the neurobiology of anxiety has focused on the generation of increased anxiety, i.e., the processes that "turn on" anxiety.
But what if the problem lay with the "off switch" instead? In other words, the dysfunction could exist in the ability to diminish anxiety once it has begun.
A new report in the current issue of Biological Psychiatry by researchers at the University of Wisconsin at Madison suggests that deficits in one of the brain's off switches for anxiety, neuropeptide Y receptors, are decreased in association with anxious temperament.
To conduct their work, the researchers studied 24 young rhesus monkeys to examine expression of the neuropeptide Y system in relation to anxious temperament. Neuropeptide Y is a neurotransmitter that helps regulate the body's response to stress. Anxious temperament is a trait that presents early in life and increases the risk of developing anxiety and depressive disorders.
They found that elevated anxious temperament is associated with decreased messenger RNA expression of two neuropeptide Y receptors, Y1R and Y5R, in the central nucleus of the amygdala, a region of the brain that plays an important role in regulating fear and anxiety.
"This finding is very important as it focuses our thinking about treatment on promoting recovery after stress rather than suppressing the normal adaptive reaction to threatening situations. Fear, at times, is the best possible reaction to life events. However, persistent fear can be destructive. This new finding points us in the direction of new treatments that aim to promote resilience rather than blunting one's life experiences," said Dr. John Krystal, Editor of Biological Psychiatry.
The authors agree, with first author Dr. Patrick Roseboom noting that "extreme anxiety in children is a prominent predictor of the later development of anxiety disorders and other illnesses such as depression and substance abuse. Using young rhesus monkeys in our model of anxious temperament is critical as brain structure and function in non-human primates closely resembles that of humans."
"Identifying the molecular underpinnings of why some individuals are at-risk for developing anxiety and depression has the potential to identify new treatment targets," added Roseboom. "The current findings suggest that focusing on a system that provides resilience may be an important strategy at the molecular level."
The article is "Neuropeptide Y Receptor Gene Expression in the Primate Amygdala Predicts Anxious Temperament and Brain Metabolism" by Patrick H. Roseboom, Steven A. Nanda, Andrew S. Fox, Jonathan A. Oler, Alexander J. Shackman, Steven E. Shelton, Richard J. Davidson, and Ned H. Kalin (doi: 10.1016/j.biopsych.2013.11.012). The article appears in Biological Psychiatry, Volume 76, Issue 11 (December 1, 2014), published by Elsevier.
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Patrick Roseboom at +1 608 263 0504 or email@example.com.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 135 Psychiatry titles and 14th out of 251 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2013 Impact Factor score for Biological Psychiatry is 9.472.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).